

CONCERT PHARMACEUTICALS, INC.

Form 8-K

June 10, 2016

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, DC 20549

---

FORM 8-K

---

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of report (Date of earliest event reported): June 10, 2016 (June 9, 2016)

Concert Pharmaceuticals, Inc.

(Exact Name of Registrant as Specified in Charter)

Delaware                      001-36310      20-4839882  
(State or Other Jurisdiction   (Commission   (IRS Employer  
of Incorporation)              File Number) Identification No.)

99 Hayden Avenue, Suite 500                      02421  
Lexington, Massachusetts  
(Address of Principal Executive Offices)   (Zip Code)  
Registrant's telephone number, including area code: (781) 860-0045

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

Item 5.07 Submission of Matters to a Vote of Security Holders.

Concert Pharmaceuticals, Inc. (the “Company”) held its Annual Meeting of Stockholders on June 9, 2016. The following is a summary of the matters voted on at that meeting.

The Company’s stockholders elected Ronald W. Barrett, Meghan FitzGerald and Wendell Wierenga as class II directors to serve until the 2019 Annual Meeting of Stockholders, each such director to hold office until his  
 1. successor has been duly elected and qualified. The results of the stockholders’ vote with respect to the election of such class II directors were as follows:

	Votes For	Votes Withheld	Broker Non-Votes
Ronald W. Barrett	12,305,169	1,845,309	4,151,321
Meghan FitzGerald	14,121,655	28,823	4,151,321
Wendell Wierenga	10,843,276	3,307,202	4,151,321

The Company’s stockholders ratified the appointment of Ernst & Young LLP as the Company’s independent  
 2. registered public accounting firm for the current fiscal year. The results of the stockholders’ vote with respect to such ratification were as follows:

Votes For	Votes Against	Votes Abstaining
18,215,997	25,346	60,456

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

CONCERT PHARMACEUTICALS, INC.

Date: June 10, 2016  
 By: /s/ Roger D. Tung  
 Roger D. Tung  
 President and Chief Executive Officer